Illumina has agreed to pay $9.8 million to settle claims related to cybersecurity vulnerabilities in its genomic sequencing products supplied to U.S. government agencies. The vulnerabilities, identified in products like Local Run Manager and Universal Copy Service, could be exploited remotely, prompting warnings from cybersecurity agencies. #Illumina #CISA #FDA #LocalRunManager #UniversalCopyService
Keypoints
- Illumina sold vulnerable genomic sequencing systems to federal agencies from 2016 to 2023.
- The company lacked a robust security program and failed to address cybersecurity vulnerabilities during product development.
- Cybersecurity agencies issued warnings about flaws in Illumina products that could allow remote hacking.
- The settlement was reached after a whistleblower lawsuit filed under the False Claims Act.
- Illumina will pay $9.8 million, with $1.9 million going to the whistleblower.